Contributions
Abstract: EP1621
Type: Poster Sessions
Abstract Category: Therapy - Neuroprotection and Repair
Background: Teriflunomide is a treatment approved for relapsing Multiple Sclerosis (MS). However, data on patients with progressive forms of MS enrolled in registrative trials showed a stabilization of disability.
Objective: To evaluate the course of disability before and under treatment with teriflunomide in patients with relapsing progressive form of MS (PMS).
Methods: Among patient treated with teriflunomide at the MS Centre of San Raffaele Scientific Institute, we selected patients with PMS and at least annual clinical evaluation in the 2 years before and the 2 years after treatment start.
Results: We selected 30 patient with PMS, 73% of which presented signs of inflammatory activity in the year before treatment start. Mean age of patients was 50 years and 63% were female. Mean disease duration was 19 years and mean baseline EDSS was 5.5. In the two years before teriflunomide start mean EDSS worsened from 4.9 to 5.5. On the contrary, during teriflunomide start mean EDSS remained stable. Delta EDSS between 2 years before and baseline was significantly different from delta EDSS between baseline and 2 years after (p=0.025).
Conclusions: Based on evidence from registrative trials suggesting potential effect of teriflunomide on disability, we started treatment in 30 patients with PMS, in most cases presenting persistent inflammatory activity. Our data, even if obtained in a small real-practice setting, showed a significant stabilization of EDSS, even in patients who presented worsening disability in the 2 years before treatment start.
Disclosure: F. Sangalli, M. Radaelli, L. Moiola, B. Colombo, F. Esposito report consultancy, speaking fees and/or travel expenses from Biogen, Merck Serono, Genzyme, Novartis. G. Comi has received compensation for consulting services and/or speaking activities from Biogen, Novartis, Teva Pharmaceutical Ind, Sanofi, Genzyme, Merck Serono, Biogen, Bayer, Actelion and Serono Symposia Int. Found, outside the submitted work. Dr. Martinelli reports consultancy, speaking fees and/or travel expenses from Biogen, Merck Serono, Bayer Schering, Novartis, Sanofi-Aventis, Genzyme Europe, Teva Pharmaceuticals, outside the submitted work. M. Pisa and G. Dalla Costa have nothing to disclose.
Abstract: EP1621
Type: Poster Sessions
Abstract Category: Therapy - Neuroprotection and Repair
Background: Teriflunomide is a treatment approved for relapsing Multiple Sclerosis (MS). However, data on patients with progressive forms of MS enrolled in registrative trials showed a stabilization of disability.
Objective: To evaluate the course of disability before and under treatment with teriflunomide in patients with relapsing progressive form of MS (PMS).
Methods: Among patient treated with teriflunomide at the MS Centre of San Raffaele Scientific Institute, we selected patients with PMS and at least annual clinical evaluation in the 2 years before and the 2 years after treatment start.
Results: We selected 30 patient with PMS, 73% of which presented signs of inflammatory activity in the year before treatment start. Mean age of patients was 50 years and 63% were female. Mean disease duration was 19 years and mean baseline EDSS was 5.5. In the two years before teriflunomide start mean EDSS worsened from 4.9 to 5.5. On the contrary, during teriflunomide start mean EDSS remained stable. Delta EDSS between 2 years before and baseline was significantly different from delta EDSS between baseline and 2 years after (p=0.025).
Conclusions: Based on evidence from registrative trials suggesting potential effect of teriflunomide on disability, we started treatment in 30 patients with PMS, in most cases presenting persistent inflammatory activity. Our data, even if obtained in a small real-practice setting, showed a significant stabilization of EDSS, even in patients who presented worsening disability in the 2 years before treatment start.
Disclosure: F. Sangalli, M. Radaelli, L. Moiola, B. Colombo, F. Esposito report consultancy, speaking fees and/or travel expenses from Biogen, Merck Serono, Genzyme, Novartis. G. Comi has received compensation for consulting services and/or speaking activities from Biogen, Novartis, Teva Pharmaceutical Ind, Sanofi, Genzyme, Merck Serono, Biogen, Bayer, Actelion and Serono Symposia Int. Found, outside the submitted work. Dr. Martinelli reports consultancy, speaking fees and/or travel expenses from Biogen, Merck Serono, Bayer Schering, Novartis, Sanofi-Aventis, Genzyme Europe, Teva Pharmaceuticals, outside the submitted work. M. Pisa and G. Dalla Costa have nothing to disclose.